![In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.](https://images.unsplash.com/photo-1766297247924-6638d54e7c89?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w5MDg5NDR8MHwxfHNlYXJjaHw5fHxtZWRpY2FsJTIwcmVzZWFyY2glMjBzY2llbmNlfGVufDF8MHx8fDE3NzU4ODUyMzd8MA&ixlib=rb-4.1.0&q=80&w=1080)
In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.
A New Scan That Lights Up Hidden Lung Cancer Spread
This prospective, phase 2, cross-sectional imaging trial evaluated [Ga]Ga-SSO120 PET/CT versus CT in 19 patients with small cell lung cancer…
A new kind of PET scan found hidden tumors in patients with aggressive lung cancer, including bone and brain spread that standard imaging mi…
SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
Precision Radiation Offers a Real Option for Lung Cancer Patients Who Can't Do Chemo
A non-randomized phase 2 trial of 50 patients with unresectable locally advanced NSCLC unfit for concurrent chemoradiation found 5-year over…
Nearly half of patients treated with precision radiation were still alive at five years, offering hope for lung cancer patients too frail fo…
AI nomogram predicts malignancy risk in surgically resected pulmonary nodules ≤3 cm
AI tool predicts cancer risk in lung nodules removed for surgery
This retrospective cohort study internally validated an AI-assisted clinico-quantitative imaging nomogram in 951 patients undergoing resecti…
An AI tool predicts cancer risk in lung nodules removed for surgery, showing a 95% chance of malignancy for high-risk cases and a 43% chance…
Spirometry restriction linked to higher interstitial lung disease and mortality risk in a large cohort.
Does normal breathing test results hide serious lung disease that leads to higher death rates?
This retrospective cohort study of 47,597 patients with normal spirometry from four pulmonary diagnostic labs found that spirometry restrict…
A normal breathing test might hide a serious lung problem that makes you three times more likely to develop scarring and 45% more likely to …
Nine patients with PPFE and DGUOK-associated mitochondriopathy show specific genetic and cellular findings.
Lung Scarring Linked to Rare Gene Defect
This review of nine cases describes patients with pleuroparenchymal fibroelastosis (PPFE) and DGUOK-associated mitochondriopathy. All patien…
A rare gene defect causes severe lung scarring in adults and children, explaining why some patients suffer from progressive shortness of bre…
FDA Approves Tyvaso (treprostinil) for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease
FDA approves new inhaled drug called Tyvaso for two serious lung conditions
The FDA approved Tyvaso (treprostinil) for pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with int…
FDA approves new inhaled drug Tyvaso to help adults with serious lung conditions improve their ability to exercise and do daily activities.
Prophylactic rhG-CSF with platinum chemotherapy improves immune markers and response rates in advanced lung cancer patients.
New drug boost may help some advanced lung cancer patients respond better to treatment
This randomized controlled trial enrolled 150 patients with advanced lung cancer at a hospital in Yuhang District. Participants receiving pr…
A new drug boost helps advanced lung cancer patients maintain stronger white blood cell counts and fight infections better during standard c…
Mindfulness interventions show mixed effects on breathlessness and pulmonary function in lung cancer patients
Mindfulness helps lung function and mood in lung cancer patients, but not breathlessness
A meta-analysis of 14 RCTs involving 1,190 lung cancer patients found mindfulness-based interventions did not significantly improve breathle…
Mindfulness improved lung function and mood for cancer patients, but it did not reduce the feeling of breathlessness.
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases.
Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Virtual wards and hospital at home show no survival or readmission benefit for ECOPD patients compared to hospital admission.
Home Hospital Care for COPD Flares Shows No Clear Win
This systematic review and meta-analysis evaluated virtual wards (VW) and hospital at home (HaH) versus hospital admission for adults with e…
Sending COPD patients home with remote monitoring did not reduce deaths or readmissions, but it also did not cause harm.
Non-cirrhotic portal fibrosis identified in 32.6% of pre-cirrhotic primary biliary cholangitis patients in a retrospective analysis.
Hidden Liver Damage Found in Early PBC
This retrospective analysis examined 92 biopsy-proven pre-cirrhotic primary biliary cholangitis (PBC) patients to characterize non-cirrhotic…
Many people with primary biliary cholangitis develop hidden liver damage called non-cirrhotic portal fibrosis before permanent scarring begi…
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
New Drug Combo Helps Some Lung Cancer Patients Live Longer
A single-arm, open-label phase Ib/II trial in 52 patients with pretreated stage IIIB/IV NSCLC adenocarcinoma found a 6-month progression-fre…
A new drug pair safely extends life for some advanced lung cancer patients who previously tried immunotherapy or have high PD-L1 markers.